SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary…

Pharvaris N.V. · PRESS-RELEASE filed May 11, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 11, 2026 at 16:15 ET

Pharvaris closed a $132.3M underwritten offering of 4.46M ordinary shares, including full exercise of the underwriters' option. The proceeds provide a significant cash runway for late-stage clinical programs, including the pivotal Phase 3 CHAPTER-3 study for HAE prevention with topline data expected in Q3 2026.

  • Closed underwritten offering of 4,455,863 ordinary shares at gross proceeds of ~$132.3M
  • Underwriters exercised option in full for an additional 581,199 shares
  • Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities acted as joint book-running managers
  • Proceeds will fund late-stage clinical programs including CHAPTER-3 Phase 3 study for HAE prevention

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access